And so, in total 132 patients had SAEs. They didn't say where these SAE occurred (before or after enrollment), and so it's unclear how many of them are related underlining GBM, to GBM standard of care or to "OTHER" treatments. And if only 7 DCVax-L patients had SAAE. And the rate of AE were approximately the same to SOC were approximately the same, to me, it indicates that it falls into the "other" bucket (I.e., Leukaphersis).
It did not say that only 7 DCVax-L patients had SAEs.
It states only 7 had SAEs related to DCVax. Patients on the DCVax arm were also on SOC, and would have received SAEs due to that. Along with both arms having non-treatment related SAEs.
Market Data 
Markets 
AI
